

Kieran F Docherty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5003738/publications.pdf>

Version: 2024-02-01

61
papers

7,003
citations

201674

27
h-index

149698

56
g-index

61
all docs

61
docs citations

61
times ranked

5948
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	27.0	4,108
2	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	7.4	340
3	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 141, 90-99.	1.6	244
4	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021, 143, 516-525.	1.6	237
5	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	1.6	193
6	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020, 41, 2379-2392.	2.2	151
7	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128
8	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021, 42, 3727-3738.	2.2	125
9	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 499.	6.1	120
10	Lung Ultrasound in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 849-858.	4.1	116
11	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 2147-2156.	7.1	91
12	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.	2.2	90
13	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. <i>JACC: Heart Failure</i> , 2021, 9, 254-264.	4.1	75
14	Statin treatment of children with familial hypercholesterolemia – Trying to balance incomplete evidence of long-term safety and clinical accountability: Are we approaching a consensus?. <i>Atherosclerosis</i> , 2013, 226, 315-320.	0.8	74
15	Effect of dapagliflozin on anaemia in <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 617-628.	7.1	57
16	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	3.9	56
17	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. <i>Circulation</i> , 2022, 146, 438-449.	1.6	53
18	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51

#	ARTICLE	IF	CITATIONS
19	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021, 44, 586-594.	8.6	50
20	How robust are clinical trials in heart failure?. <i>European Heart Journal</i> , 2017, 38, ehw427.	2.2	49
21	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 165-178.	3.0	40
22	Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021, 144, 199-209.	1.6	40
23	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 24-34.	11.4	40
24	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021, 23, 1662-1672.	7.1	36
25	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.	1.6	35
26	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 601-613.	7.1	33
27	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. <i>European Journal of Heart Failure</i> , 2022, 24, 513-525.	7.1	33
28	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. <i>European Journal of Heart Failure</i> , 2022, 24, 1066-1076.	7.1	28
29	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 678.	6.1	26
30	Sex differences in procedural and clinical outcomes following rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 232-241.	1.7	24
31	The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. <i>European Heart Journal</i> , 2021, 42, 1199-1202.	2.2	24
32	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2021, 23, 632-643.	7.1	24
33	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008837.	3.9	21
34	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020, 43, 2878-2881.	8.6	20
35	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. <i>European Journal of Heart Failure</i> , 2022, 24, 551-561.	7.1	20
36	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. <i>Korean Circulation Journal</i> , 2019, 49, 469.	1.9	18

#	ARTICLE	IF	CITATIONS
37	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
38	<sc>SOLOISTâ€W&Hf</sc> and updated metaâ€analysis: sodiumâ€glucose coâ€transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 27-30.	7.1	14
39	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.	6.1	12
40	Efficacy of Dapagliflozin in Black Versus White Patients With Heartâ€Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 52-64.	4.1	10
41	Relationship of Dapagliflozin Withâ€Serumâ€Sodium. <i>JACC: Heart Failure</i> , 2022, 10, 306-318.	4.1	10
42	Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2019, 281, 179-185.	1.7	9
43	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. <i>ESC Heart Failure</i> , 2021, 8, 129-138.	3.1	9
44	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	3.9	8
45	Sex differences in congestive markers in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2021, 8, 1784-1795.	3.1	7
46	Insights into foundational therapies for heart failure with reduced ejection fraction. <i>Clinical Cardiology</i> , 2022, 45, .	1.8	7
47	Effects of Dapagliflozin According to the Heartâ€Failure Collaboratory Medical Therapy Score. <i>JACC: Heart Failure</i> , 2022, 10, 543-555.	4.1	7
48	Phosphodiesterase-9 Inhibition in Heartâ€Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 902-904.	2.8	5
49	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk inâ€DAPA-HF. <i>JACC: Heart Failure</i> , 2022, 10, 104-118.	4.1	5
50	PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. <i>Cardiovascular Research</i> , 2019, 115, e136-e139.	3.8	2
51	<sc>OUTSTEPâ€CHF</sc>: reâ€evaluating the role of physical activity measures in drug and device development in heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 136-139.	7.1	2
52	Sodiumâ€glucose coâ€transporter 2 inhibitorsâ€the first successful treatment for heart failure with preserved ejection fraction?. <i>European Journal of Heart Failure</i> , 2021, 23, 1256-1259.	7.1	2
53	Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. <i>Heart</i> , 2022, 108, 312-320.	2.9	2
54	Effects of Dapagliflozin in Asian Patients With Heartâ€Failure and Reduced Ejection Fraction in DAPA-HF. <i>JACC Asia</i> , 2022, , .	1.5	2

#	ARTICLE	IF	CITATIONS
55	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016, 1, 93-100.	5.5	1
56	Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early?. <i>Heart</i> , 2018, 104, 1812-1813.	2.9	1
57	Genomics and Pharmacogenomics of Lipid-Lowering Therapies. , 2014, , 715-746.		0
58	Chest pain with less than 20% change in high sensitivity troponin T - a low risk cohort?. <i>Acta Cardiologica</i> , 2020, 75, 149-155.	0.9	0
59	HFrEF pharmacological treatment: angiotensin receptorâ€“neprilysin inhibitors. , 2018, , 1848-1851.		0
60	Co-morbidity (HFrEF and HFpEF): diabetes mellitus. , 2018, , 1801-1808.		0
61	Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, , .	4.0	0